ARCH Arch Biopartners Inc

Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that one of its lead scientists, Dr. Daniel Hassett, Professor at the University of Cincinnati College of Medicine, published a paper entitled “AB569, A Non-toxic Combination of Acidified Nitrite and EDTA, is Effective at Killing the Notorious Iraq/Afghanistan Combat Wound Pathogens, Multi-Drug Resistant Acinetobacter baumannii and Acinetobacter spp.” in the journal PloS One. Dr. Hassett invented AB569 at the University of Cincinnati College of Medicine.

Dr. Hassett, who collaborated with both the United States Air Force and Arch, demonstrated that AB569 kills multi-drug resistant strains of Acinetobacter baumannii and Acinetobacter spp. bacteria. These pathogens have been shown to infect soldiers who are injured by gun, shrapnel, burn or blast wounds. Nearly 40 multi-drug resistant strains of these organisms were obtained from Dr. Edwin Kamau, M.D., Chief of Molecular Diagnostics at Walter Reed Army Institute of Research (Silver Springs, MD). Acinetobacter baumannii has been colloquially referred to in the literature as "Iraqibacter", as it has emerged in a myriad of military clinics and has drastically spread to civilian hospital clinics due to transport of infected combat soldiers.

The full publication can be viewed at: https://pubmed.ncbi.nlm.nih.gov/33657146/

“Despite the attention on the current COVID-19 pandemic, the pandemic of antibiotic resistance has been ongoing for more than 50 years and will continue to loom large in human health. Sadly, the discovery of new antimicrobial drugs has slowed to a trickle. Thus, there is still an urgent need for the development of novel, cutting-edge drugs such as AB569 to help solve this deadly and costly global health problem,” said, Dr. Hassett.

Clinical Opportunity for Arch to Develop AB569

Arch is currently exploring new opportunities to sponsor a human trial to prevent, treat, and heal wound infections using an AB569 topical cream or gel. Similar clinical opportunities to test the AB569 wound cream exist in targeting abscesses, diabetic wounds and skin ulcers.

Future clinical developments may also involve using AB569 for problematic infections involving the urinary tract as well as bacterial lung infections that are a hallmark of Cystic Fibrosis and chronic obstructive pulmonary disease (COPD) airway disease.

About AB569

AB569 is a synergistic antimicrobial tandem of slightly acidified sodium nitrite and EDTA that has the critical advantage over conventional antibiotics in that it down regulates many of the genes in the bacterium responsible for survival. In a recent publication in the prestigious Proceedings of the National Academy of Sciences, Dr. Hassett’s group showed that AB569 caused a catastrophic loss of the capacity to support vital core biosynthetic and metabolic pathways of another multi-drug resistant pathogen, Pseudomonas aeruginosa. These include the synthesis of DNA, RNA, protein, ATP and the ability of bacteria to breathe by both aerobic and anaerobic respiration.

About Arch Biopartners

Arch Biopartners Inc. is a clinical stage company focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact.  Arch is developing a pipeline of new drug candidates that inhibit inflammation in the lungs, liver and kidneys via the dipeptidase-1 (DPEP-1) pathway for multiple medical indications.

Continuing under development in the Arch portfolio are: AB569, a potential new treatment for antibiotic resistant bacterial infections in the lung, wounds and urinary tract; and, ‘Borg’ peptide coatings that increase corrosion resistance and decrease bacterial biofilm on various medical grade metals and plastics.

For more information on Arch Biopartners, its technologies and other public documents Arch has filed on SEDAR, please visit www.archbiopartners.com.

The Company has 61,362,302 common shares outstanding.

Forward-Looking Statements

All statements, other than statements of historical fact, in this news release are forward looking statements that involve various risks and uncertainties, including, without limitation, statements regarding the future plans and objectives of the Company. There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statements should circumstances or management’s estimates or opinions change.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

For more information, please contact:

Richard Muruve
Chief Executive Officer
Arch Biopartners, Inc.
647-428-7031
info@archbiopartners.com